Chemotherapy and serum hyaluronic acid levels in malignant peritoneal mesothelioma

Hepato-Gastroenterology

Volumn 51, Issue 58, 2004, Pages 1073-1083

  Hotta, Tsukasa ^a   Taniguchi, Katsutoshi ^a   Kobayashi, Yasuhito ^a   Johata, Kiyofumi ^a   Sahara, Masaki ^a   Naka, Teiji ^a   Tanimura, Hiroshi ^a   Tsubota, Yukari T ^a  

^a WAKAYAMA ROSAI HOSPITAL   (Japan)

Author keywords

Chemotherapy; Hyaluronic acid; Malignant peritoneal mesothelioma

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; ACIVICIN; ACLACINOMYCIN; ALCIAN BLUE; AMSACRINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BLEOMYCIN; CARBOPLATIN; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DETORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYALURONIC ACID; HYALURONIDASE; IFOSFAMIDE; IPROPLATIN; MENOGARIL; METHOTREXATE; MITOLACTOL; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; THROMBOMODULIN; UNINDEXED DRUG; VINDESINE;

ADULT; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; CATHETERIZATION; CELL PROLIFERATION; CLINICAL FEATURE; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; ILEUM RESECTION; MALE; OMENTUM; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FLUOROURACIL; HUMANS; HYALURONIC ACID; MALE; MESOTHELIOMA; MIDDLE AGED; MITOMYCIN; PERITONEAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 3042511908     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (173)

1. Piazza D, Caruso F, Scaringi S, Ferrara M, Latteri F, Dell'erba D: Primary diffuse malignant peritoneal mesothelioma: Case report and update of therapy. J Surg Oncol 2000; 75:55-58.
2. De Bree E, Christodoulakis M, Tsiftsis B: Malignant peritoneal mesothelioma treated by continuous hyperthermic peritoneal perfusion chemotherapy. Ann Oncol 2000; 11:753-756.
3. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME: Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999; 70:6-12.
4. Daskalogiannaki M, Prassopoulos P, Raissaki M, Tsardi M, Gourtsoyiannis N: Malignant peritoneal mesothelioma presenting with respiratory symptoms. Eur Radiol 2000; 10:814-816.
5. Tani M, Tanimura H, Yamaue H, Mizobata S, Yamamoto M, Iwahashi M, Ura K, Nagai Y, Tsunoda T, Wakasaki H, Nanjo K, Fujino K, Yukawa S: Successful immunochemotherapy for patients with malignant mesothelioma: Report of two cases. Surg Today 1998; 28:647-651.
6. Ito H, Imada T, Kondo J, Amano T, Maehara T, Rino Y, Takahashi M, Shiozawa M, Hatori S, Suzuki Y: A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy. Jpn J Clin Oncol 1998; 28:145-148.
7. Muensterer OJ, Averbach AM, Jacquet P, Otero SE, Sugarbaker PH: Malignant peritoneal mesothelioma. Case-report demonstrating pitfalls of diagnostic laparoscopy. Int Surg 1997; 82:240-243.
8. Bercero EA, Perez GMGRY, Bragado FG, Jimenez C: Prognostic value of high serum levels of CA-125 in malignant secretory peritoneal mesotheliomas affecting young women. A case report with differential diagnosis and review of the literature. Histopathology 1997; 31:267-273.
9. Colbert N, Vannetzel JM, Izrael V, Schlienger M, Milleron B, Blanchon F, Herman D, Akoun G, Roland J, Chatelet F, Laugier A: A prospective study of detorubicin in malignant mesothelioma. Cancer 1985; 56:2170-2174.
10. Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP: Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68:356-362.
11. Djerassi I, Kim JS, Kasserov L, Reggev A: Response of mesothelioma to large doses of methotrexate with CF rescue used alone or with cisplatinum. Proc Am Soc Clin Oncol 1985; 4:191.
12. Solheim OP, Saeter G, Finnanger AM, Stenwig AE: High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992; 65:956-960.
13. Lerner HJ, Schoenfeld DA, Martin A, Falkson G, Borden E: Malignant mesothelioma. Proc Am Assoc Cancer Res 1981; 22:527.
14. Lerner JH, Schoenfeld DA, Martin A, Falkson G, Borden E: Malignant mesothelioma. Cancer 1983; 52:1981-1985.
15. Alberts AS, Falkson G, Zyl LV: Malignant pleural mesothelioma: Phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 1988; 80:698-700.
16. Wiltshaw E, Westbury G, Harmer C, Mckinna A, Fisher C: Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. Cancer Chemother Pharmacol 1986; 18:10-12.
17. Bajorin D, Kelsen B, Mintzer DM: Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 1987; 71:857-858.
18. Kelsen DP, Bajorin D, Mintzer D: Phase II trial of mitomycin in malignant mesothelioma. Proc Am Soc Clin Oncol 1985; 4:146.
19. Van Meerbeeck JP, Baas P, Bebruyne C, Groen HJM, Manegold CH, Ardizzoni A, Gridelli G, Galdemans D, Lenz MA, Giaccone G: Gemcitabine in malignant pleural mesothelioma: A phase II study. Lung Cancer 1988; 18:17.
20. Bishoff HG, Manegold C, Knopp M, Blatter J, Drings P: Gemcitabine may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 1998; 17:464A.
21. Bonadonna G, Beretta G, Tancini G, Brambilla C, Bajetta E, De Palo GM, De Lena M, Fossati Bellani F, Gasparini M, Valagussa P, Veronesi U: Adriamycin studies at the Instituto Nazionale Tumori, Milan. Cancer Chemother Rep 1975; 6:231-234.
22. Kucuksu N, Thomas W, Ezdinli E: Chemotherapy of malignant diffuse mesothelioma. Cancer 1976; 37:1265-1274.
23. Benjamin RS, Wiernik PH, Bachur NR: Adriamycin: A new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol 1975; 1:63-76.
24. Gottlieb JA, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SE, Bodey GP, Rodriguez VT, Blumenschein GR, Saiki JH, Coltman C, Burgess MA, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon TE: Adriamycin used alone and in combination for soft tissue and bone sarcomas. Cancer Chemother Rep 1975; 6:271-282.
25. Van Dyk JJ, Van Der Merve AM, Falkson HC, Falkson G: Adriamycin in the treatment of cancer. S Afr Med J 1976; 50:61-66.
26. Jones DEC, Silver B: Peritoneal mesotheliomas. Surgery 1979; 86:556-560.
27. Mischler NE, Chuprevich T, Johnson RO, Tormey DC: Malignant mesothelioma presenting in the pleura and peritoneum. J Surg Oncol 1979; 11:185-191.
28. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM: Diffuse malignant mesothelioma: Prospective evaluation of 69 patients. Ann Intern Med 1982; 96:746-755.
29. Antman KH, Pomfret EA, Aisner J, MacIntyre J, Osteen RT, Greenberger JS: Peritoneal mesothelioma: Natural history and response to chemotherapy. J Clin Oncol 1983; 1:386-391.
30. Lerner H, Amato D, Shiraki M, Borden E: A prospective study of adriamycin in malignant mesothelioma. Proc Am Soc Clin Oncol 1983; 2:230.
31. Vogelzang NJ, Schultz SM, Iannucci AM, Kennedy BJ: Malignant mesothelioma - the University of Minnesota experience. Cancer 1984; 53:377-383.
32. Harvey VJ, Slevin ML, Ponder BAJ, Blackshaw AJ, Wrigley PFM: Chemotherapy of diffuse malignant mesothelioma. Cancer 1984; 54:961-964.
33. Alberts AS, Falkson G, Gaedhals L, Vorobiof BA, Van Der Merwe CA: Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6:527-535.
34. Haliloglu M, Hoffer FA, Fletcher BD: Malignant peritoneal mesothelioma in two pediatric patients: MR imaging findings. Pediatr Radiol 2000; 30:251-255.
35. Gerner RE, Moore GE: Multiple drug therapy for malignant solid tumors in adults. Cancer Chemother Rep 1973; 57:237-239.
36. Gerner RE, Moore GE: Chemotherapy of malignant mesothelioma. Oncology 1974; 30:152-155.
37. Magri MD, De Giovanni D, Serra C, Crismanich F, Della Valentina M, Nicotra M, Tomasi M, Morassut S, Carbonne A, Grandi G, Monfardini S, Bianchi C: Epirubicin treatment of mesothelioma: A phase II study. Proc Am Soc Clin Oncol 1988; 7:207.
38. Mattson K, Van Breukelen FJM, Tammilehto L, Kirkpatrick A, McVie JG: 4-Epidoxorubicin in mesothelioma: A phase II study for the EORTC Lung Cancer Cooperative Group. Lung Cancer 1988; 4:A138.
39. Mattson K, Giaccone G, Kirkpatrick A, Evrard D, Tammilehto L, Van Breukelen FJ, Planteydt HT, van Zandwijk N: Epirubicin in malignant mesothelioma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1992; 10:824-828.
40. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff JH: High dose cisplatinum diammine dichloride. Cancer 1977; 39:1372-1381.
41. Samson MK, Baker LH, Benjamin RS, Lane M, Piager C: Cis- dichlorodiammineplatinum in advanced soft tissue and bony sarcomas. Cancer Treat Rep 1979; 63:11-12.
42. Dabouis G, LeMevel B, Conoller J: Treatment of diffuse pleural malignant mesothelioma by cis dichloro diammine platinum (C.D.D.P.) in nine patients. Cancer Chemother Pharmacol 1981; 5:209-210.
43. Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R: Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985; 69:711-712.
44. Zidar BL, Goldberg R, Guy J: A phase II evaluation of cisplatinum in unresectable diffuse malignant mesothelioma. Proc Am Soc Clin Oncol 1987; 6:125.
45. Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L: A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study. Invest New Drugs 1988; 6:223-226.
46. Amato DA, Borden EC, Shiraki M, Enterline HT, Rosenbaum C, Davis HL, Paul AR, Stevens CM, Lerner HJ: Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma. Invest New Drugs 1985; 3:397-401.
47. Cantwell BMJ, Franks CR, Harris AL: A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemother Pharmacol 1986; 18:286-288.
48. Gore ME, Calvert AH, Smith IE: High dose carboplatin in the treatment of lung cancer and mesothelioma: A phase I dose escalation study. Eur J Cancer Clin Oncol 1987; 23:1391-1397.
49. Mbidde EK, Harland SJ, Calvert AH, Smith IE: Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 1986; 18:284-285.
50. Vogelzang,NJ, Goutsou M, Graziano S: Carboplatin in malignant mesothelioma: A phase II study of CALGB. Proc Am Soc Clin Oncol 1989; 8:321.
51. Vogelzang NJ, Herndon II JE, Miller A, Strauss G, Clamon G, Stewart FM, Aisner J, Lyss A, Cooper MR, Suzuki Y, Green MR: High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 1999; 10:597-600.
52. Eisenhauer EA, Evans WK, Raghaven D, Desmeules MJ, Murray NR, Stuart-Harris R, Wilson KS: Phase II study of mitoxantrone in patients with mesothelioma. A National Cancer Institute of Canada Clinical Trials Group study. Cancer Treat Rep 1986; 70:1029-1030.
53. Cantwell BMJ, Earnshaw M, Harris AL: Phase II study of a novel antifolate, N-10-propargyl-5,8-dideazafolic, in malignant mesothelioma. Cancer Treat Rep 1986; 70:1335-1336.
54. Falkson G, Vorobiof DA, Lerner JH: A phase II study of m-AMSA in patients with malignant mesothelioma. Cancer Chemother Pharmacol 1983; 11:94-97.
55. Falkson G, Falkson HC: Clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D-ethylidene glucoside (NSC-141540) VP16-213. Proc Am Assoc Cancer Res 1974; 15:160.
56. Nissen NI, Larsen V, Pederson H, Thomsen K: Phase I clinical trial of a new antitumor agent, 4′-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- β-D-glucopyranoside) (NSC-141540; VP-16-213). Cancer Chemother Rep 1972; 56:769-777.
57. Nissen NI, Dombemowsky P, Hansen HH, Larsen V: Phase I clinical trial of an oral solution of VP16-213. Cancer Treat Rep 1976; 60:943-945.
58. Sahmoud D, Postmus PE, Van Pottelsberghe C, Mattson K, Tammilehto L, Splinter TA, Planting AS, Sutedja T, Van Pawel J, Van Zandwijk N, Baas P, Roozendaal KJ, Schrijver M, Kirkpatrick A, Van Glabbeke M, Ardizzoni A, Giaccone G: Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997; 33:2211-2215.
59. Hudis CA, Kelsen DP: Menogaril in the treatment of malignant mesothelioma: A phase II study. Invest New Drugs 1992; 10:103-106.
60. DiPietro S, Gennari L: Successful cyclophosphamide treatment in a case of diffuse pleural mesothelioma. Tumori 1963; 49:69-73.
61. Ridell RJ: Three cases of mesothelioma. Med J Aust 1966; 2:554-559.
62. Sørensen PG, Bach F, Bork E, Hansen HH: Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant mesothelioma. Cancer Treat Rep 1985; 69:1431-1432.
63. Yap B, Benjamin RS, Burgess MA, Bodey GP: The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma. Cancer 1978; 42:1692-1696.
64. Bautin C, Irisson M, Guerin JC, Roegel E, Paramelle B, Brambilla C, Jeannin L, Dabouis G, LeCaer H, Viallat JR: Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat Rep 1987; 71:205-206.
65. Kelsen D, Gralla R, Cheng E, Martin N: Vindesine in the treatment of malignant mesothelioma: A phase II study. Cancer Treat Rep 1983; 67:821-822.
66. Falkson G, Vorobiof DA, Simon IW, Borden E: Phase II trial of acivicin in malignant mesothelioma. Cancer Treat Rep 1987; 71:545-546.
67. Borden E, Amato D, Earhart R, Chang A: Phase II evaluation of diazonorleucine and aclacinomycin A for soft tissue or bone sarcomas and mesothelioma. Proc Am Soc Clin Oncol 1986; 5:131.
68. Volger WR, Arkun S, Velez-Garcia E: Phase I study of twice weekly 5-azacytidine (NSC-102816). Cancer Chemother Rep 1974; 58:895-899.
69. Thigpen JT, O'Bryan RM, Benjamin RS, Coltman CA: Phase II trial of Baker's antifol in metastatic sarcoma. Cancer Treat Rep 1977; 61:1485-1487.
70. Andrews NC, Weiss AJ, Ansfield FJ, Rochlin DB, Mason JH: Phase I study of dibromodulcitol (NSC-104800). Cancer Chemother Rep 1971; 55:61-65.
71. Borden E, Ash A, Rosenbaum C, Lerner H: Phase II evaluation of dibromodulcitol and maytansine in sarcomas and mesotheliomas. Proc Am Soc Clin Oncol 1980; 21:479.
72. Dhingra H, Umsawasdi T, Holoye P, Murphy W, Greenburg A, Roach R, Chun H, Raber M, Hong W: Phase II trial of 5,6-dihydroazacytidine in pleural malignant mesothelioma. Proc Am Assoc Cancer Res 1989; 30:274.
73. Eagan RT, Frytak S, Richardson RL, Creagan ET, Nichols WC: Phase II trial of diaziquone in malignant mesothelioma. Cancer Treat Rep 1986; 70:429.
74. Mártensson G, Sørenson S: A phase II study of vincristine in malignant mesothelioma - A negative report. Cancer Chemother Pharmacol 1989; 24:133-134.
75. Saijo N, Nishiwaki Y, Kawase I, Kobayashi T, Suzuki A, Niitani H: Effect of ACNU on primary lung cancer, mesothelioma and metastatic pulmonary tumors. Cancer Treat Rep 1978; 62:139-141.
76. Iriarte PV, Hananian J, Cortner JA: Central nervous system leukemia and solid tumors of childhood: treatment with 1,3-bis (2-chlorethyl)-1-nitrosourea. Cancer 1986; 19:1187-1194.
77. Garnick MB, Blum RH, Canellos GP, Mayor J, Parker L, Skarin AT, Li FP, Henderson C, Frei E: Phase I trial of bruceantin. Cancer Treat Rep 1979; 63:1929-1932.
78. Kirschner J, Delosantos R, Ziegler P, Canty R, Lawrence W, Spaulding M: Phase I/II study of high dose ara-C in solid tumors. Proc Am Soc Clin Oncol 1984; 3:44.
79. Price LA, Hill BT: Clinical use of DDMP (2,4-diamino-5-(3′5′- dichlorophenyl)-6-methyl pyrimidine). Proc Am Assoc Cancer Res 1976; 17:15.
80. Gottlieb JA, Serpick AA: Clinical evaluation of 5-(3,3-dimethyl-1- triazeno) imidazole-4-carboxamide in malignant melanoma and other neoplasms: comparison of twice-weekly and daily administration schedules. Oncology 1971; 25:225-233.
81. Chang P, Levine MA, Wiernik PH, Walker MD: A phase II trial of intravenously administered methyl CCNU in the treatment of advanced sarcomas. Cancer 1976; 37:615-619.
82. Wolcott MW, Shaver WA, Walkup HE, Peasley ED: Mesotheliomas of the pleura. Dis Chest 1959; 36:119-126.
83. Dimitrov NV, Egner J, Balcueva E, Suhrland LG: High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma. Cancer 1982; 50:1245-1247.
84. Byrne MJ, Davidson JA, Musk AW, Dewar J, Van Hazel G, Buck M, De Klerk N, Robinson BWS: Cisplatin and gemcitanine treatment for malignant mesothelioma: A phase II study. Proc Am Soc Clin Oncol 1998; 17:464A.
85. Kasseyet S, Astoul P, Boutin C: Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. Cancer 1999; 85:1740-1749.
86. Dirix Ly, Van Meerbeeck J, Schrijvers D, Corthouts B, Prové A, Van Marck E, Vermeire P, Van Oosterom AT: A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 1994; 5:653-655.
87. Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki R, McMurtrey MJ, Hong WK: Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1995; 76:2230-2236.
88. Fizazi K, Caliando R, Soulie P, Fandi A, Daniel C, Bedin A, Doubre H, Viala J, Rodier J, Trandafir L, Le Chevalier T, Cvitkovic E, Armand J, Ruffie P: Combination raltitrexed (Tomudex (R))-oxaliplatin: A step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemoimmunotherapy in mesothelioma. Eur J Cancer 2000; 36:1514-1521.
89. Tsavaris N, Primikirios N, Mylonakis N, Varouchakis G, Dosios T, Pavlidis N, Skarlos D, Tasopoulos T, Dritsas J, Kosmidis P: Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A prospective study. Anticancer Res 1997; 17:3799-3802.
90. Tsavaris N, Mylonakis N, Karvounis N, Bacoyiannis C, Briasoulis E, Skarlos D, Pavlidis N, Stamatelos G, Kosmidis P: Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 1994; 11:299-303.
91. Zidar BL, Pugh RP, Schiffer LM, Raju RN, Vaidya KA, Bloom RL, Home D, Baker LH: Treatment of six cases of mesothelioma with doxorubicin and cisplatin. Cancer 1983; 52:1788-1791.
92. Antman KH, Klegar KL, Pomfret EA, Osteen RT, Amato DA, Larson DA: Early peritoneal mesothelioma: A treatable malignancy. Lancet 1985; 11:977-981.
93. Henß H, Fiebig HH, Schildge J, Schuchhardt C, Arnold H: Treatment of advanced pleuramesothelioma with cis-platinum and adriamycin. Cancer Res Clin Oncol 1986; 111:67.
94. Henß H, Fiebig HH, Schildge J, Arnold H, Hasse J: Phase II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 1988; 11:118-120.
95. Ardizzoni A, Rosso R, DePalma M, Soresi E, Borghini U, ChiarionSileni V, Castagneto B, Scagliotti G, Brunetti I, Fusco V, Santi L: Cisplatin and adriamycin in the treatment of malignant pleural mesothelioma. A phase II FONICAP trial. Lung Cancer 1988; 4:A136.
96. Plaus WJ: Peritoneal mesothelioma. Arch Surg 1988; 123:763-766.
97. Wengrower D, Sweedan W, Gips M, Felig Y, Goldin E: Malignant peritoneal mesothelioma: Mucosal duodenal involvement and endoscopic diagnosis. Gastrointest Endosc 2000; 52:270-272.
98. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon II JE, Aisner J, Ellison RR, Leone L, Vogelzang NJ, Green MR: Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993; 11:1559-1565.
99. Chahinian AP, Holland JF, Mandel EM: Chemotherapy for malignant mesothelioma with adriamycin and continuous infusion of 5-azacytidine. Cancer Treat Rep 1978; 62:1108-1109.
100. Chahinian AP, Suzuki Y, Mandel EM, Holland JF: Diffuse pulmonary malignant mesothelioma response to doxorubicin and 5-azacytidine. Cancer 1978; 42:1687-1691.
101. Pennucci MC, Ardizzoni A, Pronzato P, Fioretti M, Lanfranco C, Verna A, Giorgi G, Vigani A, Frola C, Rosso R: Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma. Cancer 1997; 79:1897-1902.
102. Hunt KJ, Longton G, Williams MA, Livingston RB: Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 1996; 109:1239-1242.
103. Middleton GW, Smith IE, O'Brien ME, Norton A, Hickish T, Priest K, Spencer L, Ashley S: Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998; 9:269-273.
104. Gottlieb JA, Baker LH, Quagliana JM, Luce JK, Whitecar JP, Sinkovics JG, Rikvin SE, Brownlee R, Frei E: Chemotherapy of sarcomas with a combination of adriamycin and dimethyltriazeno-imidazole carboxamide. Cancer 1972; 30:1632-1638.
105. Schroeter NJ, Rushing DA, Parker JP, Beltaos E: Minimal change nephrotic syndrome with malignant mesothelioma. Arch Intern Med 1986; 146:1834-1836.
106. Dhingra H, Valdivieso M, Tannir N, Booser DJ, Frazier OH, Benjamin RS: Combined modality treatment for mesothelioma with cytoxan and adriamycin and DTIC and adjuvant surgery. Proc Am Soc Clin Oncol 1983; 2:205.
107. Rivera FJ: Malignant peritoneal mesothelioma: A difficult diagnosis. Iowa Med 1986; 76:222-224.
108. Samson MK, Wasser LP, Borden E, Wanebo HJ, Creech RH, Phillips M, Baker LH: Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: A Sarcoma Intergroup study. J Clin Oncol 1987; 5:86-91.
109. Pomflet E, Antman KH, Corson J, MacIntyre J, Price K, Greenberger J, Osteen R, Collins J: Intensive treatment of patients with malignant mesothelioma. Proc Am Assoc Cancer Res 1983; 24:156.
110. Antman KH, Cohen S, Dimitrov NV, Green M, Muggia F: Malignant mesothelioma of the tunica vaginalis testis. J Clin Oncol 1984; 2:447-451.
111. Samuels BL, Herndon II JE, Harmon DC, Carey R, Aisner J, Corson JM, Suzuki Y, Green MR, Vogelzang NJ: Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B. Cancer 1998; 82:1578-1584.
112. Law MR, Gregor A, Hodson ME, Bloom HJG, Turner-Warwick M: Malignan mesothelioma of the pleura: A study of 52 treated and 64 untreated patients. Thorax 1984; 39:255-259.
113. Fer MF, Beatty PG, Richardson RL, Greco FA: Combination chemotherapy of malignant mesothelioma with cyclophosphamide, adriamycin and vincristine. Cancer Chemother Pharmacol 1980; 4:135.
114. Brenner J, Sordillo PP, Magill GB: Malignant mesothelioma in children: Report of seven cases and review of the literature. Med Pediatr Oncol 1982; 9:367-373.
115. Spremulli E, Wampler G, Becelson W, Borochowitz D, Hapdy T: Chemotherapy of malignant mesothelioma. Cancer 1977; 40:2038-2045.
116. Gottlieb JA, Bodey GP, Sinkovics JG, Rodriguez VT, Burgess MA: An effective new drug combination (CYVADIC) for metastatic sarcomas. Proc Am Assoc Cancer Res 1974; 15:162.
117. Sauer H, Kremer G, Wilmanns W: Zur Toxizität einer CYVADIC-Modifikation bei Patienten mit Weichteilsarkomen oder malignen Mesotheliomen. Onkologie 1987; 10:294-300.
118. Chahinian AP, Norton L, Szrajer L, Holland JF: Mitomycin C and cisplatin in human malignant mesothelioma xenografts in nude mice: Clinical correlation. Proc Am Assoc Cancer Res 1983; 24:151.
119. Chahinian AP, Norton L, Holland JF, Szrajer L, Hart RD: Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma. Cancer Res 1984; 44:1688-1692.
120. Magri MD, Foladore S, Veronesi A, Serra C, Nicotra M, Tommasi M, Grandi G, Monfardini S, Blanchi C: Treatment of malignant mesothelioma with epirubicin and ifosfamide: A phase II cooperative study. Ann Oncol 1992; 3:237-238.
121. Andersen MK, Krarup-Hansen A, Martensson G, Winther-Nielsen H, Thylen A, Damgaard K, Olling S, Wallin J: Ifosfamide in malignant mesothelioma: A phase II study. Lung Cancer 1999; 24:39-43.
122. Zidar BL, Metch B, Balcerzak SP, Pierce HI, Militello L, Keppen MD, Berenberg JL: A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. Cancer 1992; 70:2547-2551.
123. Falkson G, Hunt M, Borden EC, Hayes JA, Falkson CI, Smith TJ: An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992; 10:337-343.
124. Brenner DE, Chang P, Wiernik PH: Doxorubicin and dactinomycin therapy for advanced sarcomas. Cancer Treat Rep 1981; 65:231-236.
125. Klastersky J, Sculier JP, Tueni E: A phase I study of a carboplatin and etoposide chemotherapy in patients with advanced thoracic cancer. Proc Am Soc Clin Oncol 1987; 6:184.
126. Jett JR, Eagan RT: Chemotherapy for malignant mesothelioma. Am J Clin Oncol 1982; 5:429-431.
127. Zidar BL, Benjamin RS, Frank J, Lane M, Baker LH: Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC. Am J Clin Oncol 1983; 6:71-74.
128. Knuuttila A, Ollikainen T, Halme M, Mali P, Kivisaari L, Linnainmaa K, Jekunen A, Mattson K: Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma-A feasibility study. Anticancer Drugs 2000; 11:257-261.
129. Creagan ET, Hahn RG, Ahmann DL, Edmonson JH, Bisel HF, Eagan RT: A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide and vincristine and a single agent, methyl-CCNU, in advanced sarcomas. Cancer Treat Rep 1976; 60:1385-1387.
130. Samson MK, Baker LH, Devos JM, Buroker TR, Izbicki RM, Vaitkevicius VK: Phase I trial of combined therapy with vinblastine, bleomycin, and cis-dichlorodiamine-platinum. Cancer Treat Rep 1976; 60:91-97.
131. Etoh T, Baba H, Adachi E, Kohnoe S, Seo Y, Saito T, Tomoda H, Fukuda T, Tsukamoto N: A case of liver metastasis of malignant peritoneal mesothelioma successfully treated by surgery. Oncol Rep 1997; 4:803-805.
132. Tucker WG, Talley RW, Brownlee RW, Burrows JH, Stott PB, Moorhead EL, San Diego EL: Preliminary trials with combination therapy of cyclophosphamide, vincristine and 5-fluorouracil. Cancer Chemother Rep 1968; 52:593-596.
133. Lederman GS, Recht A, Herman T, Osteen R, Corson J, Antman KH: Long-term survival in peritoneal mesothelioma-the role of radiotherapy and combined modality treatment. Cancer 1987; 59:1882-1886.
134. Weissmann L, Osteen R, Cosron J, Hetman T, Antman KH: Combined modality therapy for intraperitoneal mesothelioma. Proc Am Soc Clin Oncol 1988; 7:274.
135. Vlasveld LT, Gallee MPW, Rodenhuis S, Taal BG: Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur J Cancer 1991; 27:732-734.
136. Blöshl-Daum B, Eichler HG, Rainer H, Jakesz R, Salzer H, Steger G, Schüller J, Günther E, Proksch B, Ehninger G: Escalating dose regimen of intraperitoneal mitoxantrone: Phase I study-Clinical and pharmacokinetic evaluation. Eur J Cancer Clin Oncol 1988; 24:1133-1138.
137. Vlasveld LT, Taal BG, Kroon BBR, Gallee MPW, Rodenhuis S: Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. Cancer Chemother Pharmacol 1992; 29:405-408.
138. Markman M, Kelsen D: Intraperitoneal cisplatin and mitomycin as treatment for malignant mesothelioma. Reg Cancer Treat 1989; 2:49-53.
139. Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF: Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol 1985; 20:1-9.
140. Ehninger G, Rückle H, Haag C, Wilms K: Die Therapie der Peritonealkarzinose mit intraperitonealer Gabe von cis-Diaminodichloroplatin und systemischer Natriumthiosulfatprotektion-klinische Ergebnisse einer Pilotstudie und Pharmakokinetik. Onkologie 1985; 8:202-206.
141. Markman M, Kelsen D: Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118:547-550.
142. Howell SB, Pfeifle CL, Wung WE, Ohlsen RA, Lucas WE, Yon JL, Green M: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982; 97:845-851.
143. Pfeifle CE, Howell SB, Markman M: Intracavitary cisplatin chemotherapy for mesothelioma. Cancer Treat Rep 1985; 69:205-207.
144. Krmani S, Cleary SM, Mowry J, Howell SB: Intracavitary cisplatin for malignant mesothelioma: An update. Proc Am Soc Clin Oncol 1988; 7:273.
145. Markman M, Cleary S, Pfeifle CE, Howell SB: Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 1986; 58:18-21.
146. Langer CJ, Rosenblum N, Hogan M, Nash S, Bagchi P, LaCreta FP, Catalano H, Comis RL, O'Dwyer PJ: Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: Favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 1993; 32:204-208.
147. Roberts GH, Irvine RW: Peritoneal mesothelioma-A report of 4 cases. Br J Surg 1970; 57:645-650.
148. Markman M, Howell SB: Daily intraperitoneal administration of cytarabine in a patient with peritoneal mesothelioma. Cancer Drug Deliv 1985; 2:285-289.
149. Westermann AM, Dubbelman R, Moolenaar WH, Beijnen J, Rodenhuis S: Successful intraperitoneal suramin treatment of peritoneal mesothelioma. Ann Oncol 1997; 8:801-802.
150. Markman M, Cleary S, Lucas WE, Howell SB: Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian cancer and other malignancies principally involving the peritoneal cavity. J Clin Oncol 1985; 3:925-931.
151. Moore MLG, Savaraj N, Feun LG, Donnelly E: Successful therapy of peritoneal mesothelioma with intraperitoneal chemotherapy alone. Am J Clin Oncol 1992; 15:528-530.
152. Budd GT, Schreiber MJ, Steiger E, Bukowski RM, Weick JK: Phase I trial of intraperitoneal chemotherapy with 5-fluorouracil and citrovorum factor. Invest New Drugs 1986; 4:155-158.
153. Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti SK, Alexander HR: Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am 1997; 3:174-179.
154. Mongero LB, Beck JR, Kroslowitz RM, Argenziano M, Chabot JA: Treatment of primary peritoneal mesothelioma by hyperthemic intraperitoneal chemotherapy. Perfusion 1999; 14:141-145.
155. Soulié P, Ruffié P, Trandafir L, Monnet I, Tardivon A, Terrier P, Cvitkovic E, Le Chevalier T, Armand JP: Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 1996; 14:878-885.
156. Trandafir L, Ruffie P, Borel C, Monnet I, Soulie P, Adams D, Cvitkovic E, Armand JP: Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. Eur J Cancer 1997; 33:1900-1902.
157. Tansan S, Emri S, Selcuk T, Koc Y, Hesketh P, Heeren T, McCaffrey R, Baris YI: Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha Interferon. Oncology 1994; 51:348-351.
158. Upham JW, Musk AW, Van Hazel G, Byrne M, Robinson BW: Interferon alpha and doxorubicin in malignant mesothelioma: A phase II study. Aust NZ J Med 1993; 23:683-687.
159. O'Reilly EM, Ilson DH, Saltz LB, Heelan R, Martin L, Kelsen DP: A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. Cancer Invest 1999; 17:195-200.
160. Bretti S, Berruti A, Dogliotti L, Castagneto B, Bertulli R, Spadaro P, Toscano G, Astorre P, Verusio C, Lionetto R, Bruzzi P, Santoro A: Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: A multicenter phase II study of the Italian Group on Rare Tumors. Tumori 1998; 84:558-561.
161. Sone S, Tsubura E: Mesothelioma and local immunotherapy. Ann Intern Med 1978; 88:575.
162. Thylén A, Wallin J, Martensson G: Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma. Cancer 1999; 86:2000-2005.
163. Atagi S, Ogawara M, Kawahara M, Sakatani M, Furase K, Ueda E, Yamamoto S: Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: Likelihood ratios for malignant mesothelioma. Jpn J Clin Oncol 1997; 27:293-297.
164. Martensson G, Thylen A, Lindqvist U, Hjerpe A: The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods. Cancer 1994; 73:1406-1410.
165. Clark JR, Ross WB: An unusual case of ascites: Pitfalls in diagnosis of malignant peritoneal mesothelioma. Aust NZ J Surg 2000; 70:384-388.
166. Krarup-Hansen A, Hansen HH: Chemotherapy in malignant mesothelioma: A review. Cancer Chemother Pharmacol 1991; 28:319-330.
167. Heller DS, Gordon RE, Clement PB, Turnnir R, Katz N: Presence of asbestos in peritoneal malignant mesotheliomas in women. Int J Gynecol Cancer 1999; 9:452-455.
168. Sato F, Yamazaki H, Ataka K, Mashima I, Suzuki K, Takahashi T, Umezu H, Gejyo F: Malignant peritoneal mesothelioma associated with deep vein thrombosis following radiotherapy for seminoma of the testis. Intern Med 2000; 39:920-924.
169. Iwahashi M, Nakamori M, Tani M, Yamaue H, Sakaguchi S, Nakamura M, Ueda K, Ichiro M, Nishino E, Tanimura H: Complete response of highly advanced gastric
170. Rogoff EE, Hilaris BS, Huvos AG: Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation. Cancer 1973; 32:656-664.
171. Rose RG, Palmer JD, Lougheed MN: Treatment of peritoneal mesothelioma with radioactive colloidal gold. Report of a case. Cancer 1955; 8:478-481.
172. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Mornar-Kimber K, Recio A, Knox L, Wilson JM, Albelda SM, Kaiser LR: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9:1083-1092.
173. Hotta T, Tanimura H, Tsunoda T, Iwahashi M, Tani M, Noguchi K, Mizobata S, Arii K, Terasawa H, Nakamori M, Yamaue H: P-glycoplotein expression and chemosensitivity in highly purified fresh human gastrointestinal cancer cells. Hepatogastroenterology 1999; 46:316-321.